While it may have one of the broadest biosimilar pipelines in the industry, with 24 assets in various stages of development and regulatory filing, Sandoz will continue to focus on the quality of its future offerings, especially as new and uncharted opportunities arise at the beginning of the next decade.
“You need to be really thinking how do I select the assets? What needs to be in place from a regulatory point of view in terms of streamlining development and having a leaner pathway? And also, about having the right benefit sharing schemes in order to make that effective
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?